Intelligence · Patents
Patents expiring in 2027
Annual patent cliff calendar for 2027 — US pharmaceutical patents by expiration date.
- Patents
- 578
Quick answer
578 indexed pharmaceutical patents have expiration dates in 2027. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 7303754
MVA expressing modified HIV envelope, gag, and pol genes
granted -
US 7303751
Anti-plasmodium compositions and methods of use
granted -
US 7303748
Method of treating eye injury with local administration of a VEGF inhibitor
granted -
US 7303747
Use of VEGF inhibitors for treatment of eye disorders
granted -
US 7303746
Methods of treating eye disorders with modified chimeric polypeptides
granted -
US 7306804
HIV-specific T-cell induction
granted -
US 7306799
Use of VEGF inhibitors for treatment of eye disorders
granted -
US 7306627
Acellular matrix grafts of collagen and elastic fiber
granted -
US 7306946
Antifungal polypeptides
granted -
US 7306632
Leave-in color conditioner
granted -
US 7306787
Engineered particles and methods of use
granted -
US 7306806
Recombinant P. falciparum merozoite protein-142 vaccine
granted -
US 7306914
Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy
granted -
US 7307075
Tetrahydroquinoline analogues as muscarinic agonists
granted -
US 7306808
Orientia tsutsugamushi truncated recombinant outer membrane protein (r47) and (r57) vaccines diagnostics and therapeutics for scrub typhus
granted -
US 7307103
Sodium dodecyl sulfate compositions for inactivating prions
granted -
US 7309694
Modified cytokines for use in cancer therapy
granted -
US 7309483
Method of treatment using Tie2 ligand2
granted -
US 7309774
Antiplasmin cleaving enzyme
granted -
US 7309792
Dimeric small molecule potentiators of apoptosis
granted -
US 7309716
Benzimidazoles useful as modulators of ion channels
granted -
US 7309702
Arylpiperazines having activity at the serotonin 1A receptor
granted -
US 7309693
Preventives and remedies for pulmonary hypertension
granted -
US 7309495
Hemorrhagic feline calicivirus
granted -
US 7309692
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
granted -
US 7312228
Cytotoxic indeno and isoindoloisoquinolones
granted -
US 7311911
Methods for inhibiting angiogenesis
granted -
US 7312202
Rationally designed and chemically synthesized promoter for genetic vaccine and gene therapy
granted -
US 7312226
Substituted tricyclic compounds as protein kinase inhibitors
granted -
US 7312227
Compositions useful as inhibitors of JAK and other protein kinases
granted -
US 7312231
Quinuclidine carbamate derivatives and their use as M3 antagonists
granted -
US 7312340
Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one
granted -
US 7312301
Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof
granted -
US 7311921
Multi-subtype FIV vaccines
granted -
US 7311916
Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41
granted -
US 7312198
Protein compositions for promoting wound healing and skin regeneration
granted -
US 7314858
Retrocyclins: antiviral and antimicrobial peptides
granted -
US 7314885
Pyrrole compounds useful as kinase inhibitors
granted -
US 7314625
Chimeric protein comprising non-toxic Pseudomonas exotoxin A and Type IV pilin sequences
granted -
US 7314917
Modified vitamin K-dependent polypeptides
granted -
US 7314624
Nanoemulsion vaccines
granted -
US 7314887
Thrombopoietin activity modulating compounds and methods
granted -
US 7314615
IκB Kinase-β (IKKβ) binding antibodies and methods of using same
granted -
US 7314618
Antibodies to fibroblast growth factor (FGF23)
granted -
US 7314956
Multifunctional carrier for the delivery of a pharmacological agent or genetic material into a cell
granted -
US 7314911
Prostate hyperplasia therapy
granted -
US 7314731
Method for selecting therapeutic agents for cancer
granted -
US 7314631
Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
granted
Frequently asked questions
How many pharma patents expire in 2027?
578 published patents in our USPTO index have expiration dates falling in calendar year 2027.